Loading in 2 Seconds...
Loading in 2 Seconds...
WALDENSTROM’S MACROGLOBULINEMIA. MISSION AND PURPOSE. • Provide encouragement and support to WM patients and caregivers; • Provide a means for patients and caregivers to communicate;
MISSION AND PURPOSE
• Provide encouragement and support to WM patients and caregivers;
• Provide a means for patients and caregivers to communicate;
• Provide information and educational programs that addresses the concerns of patients and their caregivers;
• Increase awareness of the issues related to WM;
• Encourage and support research toward more effective treatments and a ultimately finding cure.
October 10th 2010 Venice, Italy
Waldenstrom’s macroglobulinemia (WM) is a neoplasm of small B lymphocytes, plasmacytoid lymphocytes, and plasma cells; bone marrow involvement and an IgM monoclonal gammopathy of any concentration.
The assessment of treatment response in WM patients relies heavily on changes in serum IgM concentration.
This may be misleading because of the following phenomena:
- Variability in the presenting IgM levels and additional clinical parameters between patients;
- Changes in IgM do not always result in the improvement of symptoms;
- Kinetics of IgM reduction and the effect of the treatment regimen used. Responses to some drugs (alkylating agents, purine analogues and monoclonal antibodies) are typically slow whereas responses to other drugs (Velcade) are rapid.
There may be discrepancies between IgM and BM responses:
1. great bone marrow responses may be seen in patients with small reductions in IgM (selective depletion of B cells and persistence of the plasma cell component of the disease);
2. rapid drops in serum IgM levels may be seen with poor bone marrow and lymph node responses in some patients treated with bortezomib (Velcade);
FROM: Dr. Roger Owen, HMDS Laboratory, St James's Institute of Oncology, Leeds, UK.
BONE MARROW BIOPSIES ARE THE BEST!
- there is progressive depletion of normal B-cells over time. The depletion is independent of whether the B-cell disorder is stable or progressive.
FROM: Dr. Any Rawstron, HMDS Laboratory, St James's Institute of Oncology, Leeds, UK.
Be vigilant, not complacent!
THINGS ARE GETTING BETTER!“Perhaps our eyes need to be washed by our tears once in a while, so that we see life with a clearer view again.”
STAY INFORMED AND YOU WILL LIVE LONGER!
“If it works in Multiple Myeloma it must work in WM”
Drugs may have very different effects and toxicity profiles than in MM. Investigators need to be careful not to use the drugs in WM too much by analogy with Myeloma
Increase in CNS tumors; long-term immune system dysfunction, long-term side-effects of treatment...
DONATE AND PARTICIPATE!